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Like all viruses, the SARS-CoV-2 virus mutates over time, creating new viral variants that have 
the potential to transmit more rapidly, cause more severe disease, or avoid treatment and 
prevention strategies. A critical component of the public health response to COVID-19 is 
identifying and tracking the emergence of SARS-CoV-2 variants. In West Virginia, this effort is 
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Following the initial outbreak of COVID-19 in December 2019 and its spread to the United 
States in the following two months, initial efforts were focused on quickly and accurately 
diagnosing the disease. The predominant form of test developed uses reverse real-time reverse-
transcriptase polymerase chain reaction (rRT-PCR) on samples, typically obtained via a 
nasopharyngeal swab. rRT-PCR is a common and relatively simple laboratory procedure and in 
the United States a number of commercial laboratories who were already equipped to perform 
this test quickly mobilized to provide large-capacity testing nationwide. 
 
As with all viruses, the RNA replication of SARS-CoV-2, the virus causing COVID-19, is 
imperfect. Because of this, new genetic variants of the virus emerge over time. Some of these 
genetic variants, particularly those involving specific mutations in the S gene, which translates to 
the spike protein, confer evolutionary advantages1. These advantages may include increased 
transmissibility and/or the potential for more severe disease and as such pose an increased public 
health risk. There is the potential for genetic variation in the virus to cause decreased 
susceptibility to treatment or vaccination. At the time of writing, the Centers for Disease Control 
(CDC) has classified five specific variants as “variants of concern”. Using the PANGOLIN 
nomenclature, these variants of concern are B.1.1.72, first discovered in the United Kingdom in 
October 2020, B.1.3513, first seen in South Africa in December 2020, P.14, first observed in 
Japan in January 2021 in patients who had recently traveled from Brazil and later observed in 
samples from Brazil which were collected in December 2020, and B.1.427 and B.1.4295, which 
were both first observed in California in July 2020. The CDC has identified three further variants 
which are classified as “variants of interest”. The “variants of high consequence” category, 
which is intended for the variants most threatening to public health, currently has no variants 
assigned to it. 
 
Identifying and tracking the prevalence of genetic variants of SARS-CoV-2 has become a public 
health priority. By identifying SARS-CoV-2 variants, epidemiologists can identify which 
variants have increased transmissibility as well as detect occurrences of known variants of 
concern. This in turn allows them to rapidly perform contact tracing and, if necessary, implement 
public health policies to mitigate the spread of more transmissible forms of the virus. 
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Determining the variant of a particular viral sample requires sequencing all 29,903 nucleotides in 
the viral genome. By contrast to diagnostics by rRT-PCR, this requires highly specialized, high-
throughput sequencing technology and technical expertise both in laboratory processes and in 
data analysis. 
 
In December 2020, the West Virginia “Coronavirus Czar” and Dean of the School of Medicine at 
West Virginia University, Dr. Clay Marsh, asked Dr. Laura Gibson, senior vice president for 
research at the WVU Health Sciences Center, to assemble a team to perform viral sequencing 
from positive SARS-CoV-2 samples from across the state. Dr. Gibson leveraged the genomics 
core facilities at WVU and Marshall University, the bioinformatics core facility at Marshall 
University, the state epidemiology laboratory at the WV Department of Health and Human 
Resources (DHHR), and WVU and commercial testing facilities across the state in order to 
develop a pipeline to identify SARS-CoV-2 variants. The WVU and Marshall University 
components of this team have a record of close collaboration spanning over a decade. The 
development of this pipeline requires complex logistics in moving samples from testing labs to 
sequencing labs and maintaining records of the origin of each sample while protecting private 
health information. Sequencing laboratory protocols had to be tested and optimized. A data 
analysis pipeline had to be developed, and high-performance computing resources were required 
in order to run it. Information management protocols for dissemination of occurrences of variants 
of concern to the DHHR and the state governor’s coronavirus task force had to be implemented. 
The first sequencing run was completed on February 19th 2021 at the WVU genomics core 
facility and resulted in the detection of three samples with the B.1.1.7 variant. At the time of 
writing, eight sequencing runs have been completed, identifying the variant of 1,686 individual 
samples. These samples are drawn both from “surveillance” of predominantly asymptomatic 
subjects and clinical samples from symptomatic patients. The resulting data set can be used, for 




Figure 1:  Change in distribution of selected SARS-CoV-2 variants in West Virginia among 
sequenced clinical (left panel) and surveillance (middle panel) samples, showing the emergence 
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and eventual dominance of B.1.1.7 over the B.1.2 variant. For comparison, the distribution 
across the USA over the same time period is shown (right panel), using data downloaded from 
NCBI GenBank.  
 
All five variants of concern have been detected in the state. The last to be detected was P.1 on 
April 16th 2021; contact tracing was initiated and the public was informed within hours of the 
completion of sequencing in the laboratory. Sequences from these samples, along with metadata, 
have been submitted to the Global Initiative on Sharing All Influenza Data (GISAID) in order to 
contribute to global epidemiology and other data analyses.  
 
The rapid development of this pipeline was only possible by leveraging specific technical 
expertise, dedicated specialized equipment, and existing collaborations that are almost uniquely 
present in academic environments. The academic core facilities that provide this functionality are 
supported in part by investments in the form of grant funding from the National Institute for 
General Medical Sciences. The academic entities collaborate with corporate laboratories that 
provide the positive samples and the DHHR who enact the public health policies in response to 
the scientific findings.  
 
This one-of-a-kind, public-private-academic partnership demonstrates the value of public 
investment in academic institutions and how the ongoing support of science can contribute to the 
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